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Abstract
Nonalcoholic fatty liver disease (NAFLD) is emerging 
as the most common chronic liver disease, and is 
characterized by a wide spectrum of fat-liver disorders 
that can result in severe liver disease and cirrhosis. 
Inflammation and oxidative stress are the major 
risk factors involved in the pathogenesis of NAFLD. 
Currently, there is no consensus concerning the 
pharmacological treatment of NAFLD. However, lifestyle 
interventions based on exercise and a balanced diet for 
quality and quantity, are considered the cornerstone 
of NAFLD management. Mediterranean diet (MD), rich 
in polyunsaturated fats, polyphenols, vitamins and 
carotenoids, with their anti-inflammatory and anti-
oxidant effects, has been suggested to be effective in 
preventing cardiovascular risk factors. In adults, MD has 
also been demonstrated to be efficacious in reducing 
the risk of metabolic syndrome. However, few studies 
are available on the effects of the MD in both adult 
and pediatric subjects with NAFLD. Thus, the aims of 
the present narrative review are to analyze the current 
clinical evidence on the impact of MD in patients with 
NAFLD, and to summarize the main mechanisms of 
action of MD components on this condition.
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Core tip: Lifestyle interventions based on exercise and 
a balanced diet, are considered the cornerstone of 
nonalcoholic fatty liver disease (NAFLD) management. 
The Mediterranean diet (MD), low in saturated fats and 
animal protein, high in antioxidants and fibers, and 
with an adequate omega-3 to omega-6 fatty balance, 
has been suggested to be effective in NAFLD. Although 
the results from the available studies are encouraging, 
there is still need of trials with larger sample size, along 
with the standardization of the criteria to evaluate 
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adherence to the diet, before including the MD as a 
therapeutic dietary pattern in NAFLD.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is one of the 
most common causes of chronic liver disease[1,2]. It re­
presents a wide range in liver damage that may lead to 
severe liver disease such as cirrhosis and hepatocellular 
carcinoma[3]. Adults as well as children with fatty 
liver display abnormal glucose and lipid metabolism. 
Therefore, NAFLD is now considered an important 
component of the metabolic syndrome (MetS)[4]. The 
mechanism of liver injury in NAFLD is considered to 
be a “multiple­hit process”. The first “hit” leads to an 
increase in liver fat, while the next multiple factors lead 
to inflammation[5]. Indeed, the early manifestation of 
NAFLD is triglyceride accumulation in the liver associated 
with insulin resistance, which is considerably affected 
by factors such as hyperenergetic diets, sedentary 
lifestyle, and genetic susceptibility. Fat accumulation in 
the liver is associated with lipotoxic hepatocellular injury 
due to elevated free fatty acids, free cholesterol and 
other lipid metabolites. Thus, mitochondrial dysfunction 
with oxidative stress and endoplasmic reticulum stress­
associated mechanisms are activated[6]. 
Obesity is considered a key player in the develop­
ment of NAFLD, and the majority of patients with 
NAFLD are either obese or overweight. However, 
NAFLD has been reported also in lean subjects. 
“Lean” NAFLD represents subpopulation of patients 
with fatty liver and normal BMI. These patients are 
usually insulin resistant and have low HDL­C and 
higher triglyceride concentrations when compared to 
lean healthy controls[7]. Visceral obesity (as opposed 
to general obesity), insulin resistance, high fructose 
and high cholesterol intake are the most prevalent 
risk factors for lean NAFLD, although genetic factors 
(e.g., Palatin­like phospholipase domain ­containing 
3 and Transmembrane 6 superfamily member 2 gene 
variants) may have an important role.
NAFLD diagnosis requires proof of steatosis, which 
relies on imaging techniques in clinical practice. Liver 
biopsy remains the gold standard to address such 
diagnosis and is the only valid method for differentiating 
NASH from simple steatosis, however it is neither 
feasible nor ethical to perform liver biopsy as a tool in 
all putative patients. Noninvasive imaging techniques, 
such as ultrasound (US), computed tomography 
(CT), magnetic resonance imaging (MRI), and proton 
magnetic resonance spectroscopy (MRS), can also 
identify fatty infiltration of the liver[8­10]. US is perhaps 
the most practical way to assess hepatic steatosis, due 
to its relatively low cost, availability, and safety. A major 
limitation of this operator­dependent technique is its 
limited sensitivitiy and specificity for diagnosing and 
quantifying hepatic steatosis. MRS is considered the 
non­invasive reference standard in the assessment of 
liver steatosis, because it is able to measure the real 
concentration of triglycerides within the hepatocytes. 
However, MRS is too time consuming for routine 
clinical practice, and requires a skilled operator to 
correctly perform the examination, process the data, 
and interpret the results. MRI has shown greater 
promise for the quantitative assessment of hepatic 
steatosis in adults and children. Until recently, the most 
widely used method was based on the modified Dixon 
technique[8]. This imaging method is reliable in the 
absence of magnetic field non­homogeneity and iron 
deposition. Recent improvement in MRI have provided 
measurement of the proton density fat­fraction [(PDFF): 
The fraction of the liver proton density attributable to 
liver fat],which is a inherent property of tissue and a 
direct measure of liver fat content. MRI­PDFF is accu­
rate, precise, and reliable for quantifying liver steatosis 
having been validated against liver biopsy in both adults 
and children[9,10].
Currently, there is no agreement with respect to the 
pharmacological treatment of NAFLD. However, lifestyle 
interventions based on exercise and a balanced diet for 
quality and quantity, are considered the cornerstone 
of NAFLD management[11]. Mediterranean diet (MD), 
which is characterized by a significant amount of 
fibers, polyunsaturated fats and antioxidants, has 
been suggested to decrease the risk of cardiovascular 
diseases (CVD). In adults, MD has also been demon­
strated to be efficacious in reducing the risk of 
MetS[12­15]. However, few studies are available on the 
effects of MD in both adults and children with NAFLD. 
Thus, the present narrative review aims to present 
an analysis of the available literature on the effects of 
the MD in patients with NAFLD, and to summarize the 
main mechanisms of action of MD components on this 
condition. To identify relevant studies, a systematic 
literature search on MEDLINE and EMBASE databases 
was conducted using the following keywords: “Mediter­
ranean diet”, “nonalcoholic fatty liver disease”, “hepatic 
steatosis”, “steatohepatitis”. All searches were limited 
to studies published in English language
DIET IN NAFLD TREATMENT
Results of studies regarding pharmacological options for 
treatment of NAFLD are inconclusive[11]. At the moment 
the best treatment to manage NAFLD is lifestyle 
intervention to achieve weight loss[11]. A 7% to 10% 
body weight reduction after energy restriction and/or 
regular physical activity is associated with histological 
improvement, resolution of liver fat, necroinflammation 
and fibrosis[16,17]. Though weight loss is considered the 
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most effective treatment in NAFLD, some diets that 
involve excessive and/or rapid weight loss (e.g, very 
low carbohydrate, high fat diets) may actually cause or 
exacerbate the disease, inducing insulin resistance[18,19]. 
As weight reduction is a consequence of physical activity 
and a ‘healthy diet’, dietary habits rather than weight 
loss per se may improve NAFLD[18]. Dietary treatment 
to achieve weight loss must have not only quantitative 
but also qualitative characteristics. Most studies 
conclude that energy restriction alone is not enough to 
treat NAFLD[20], and that the composition of the diet, 
with modulation of both macro and micronutrients, 
is crucial[21]. Therefore, a balanced nutrition and a 
moderate weight loss can now be considered as the 
best therapeutic approach in NAFLD. According to 
international guidelines, the first step for treating NAFLD 
is to limit the intake of calories, of fats (saturated fatty 
acids, trans fatty acids), and of fructose and, conversely, 
to increase the intake of lean protein, fibers, and n­3 
polyunsaturated fatty acid (PUFA)[15]. Indeed, MD 
appears as a useful dietary option to produce weight 
loss followed by concomitant metabolic benefit for 
NAFLD. 
MEDITERRANEAN DIET
MD is a nutritional model which has its origins in the 
States surrounding the Mediterranean Sea. It was 
therefore traditionally used by the populations living 
in these regions. Although MD pattern may vary 
among countries and regions owing to cultural, ethnic, 
religious and agricultural differences, the common MD 
pattern consists of eating primarily unrefined cereals, 
vegetables and fresh fruit, olive oil, and nuts; eating 
fish, white meat and legumes in moderation; limiting 
red meat, processed meats and sweets; and drinking 
red wine in moderation (Table 1). Therefore, the main 
characteristics of MD are beneficial fatty acid profile 
consisting of a low consumption of saturated fat and 
cholesterol, and, conversely, of a high consumption of 
monounsaturated fatty acid (MUFA) with a balanced 
PUFA omega­6 to omega­3 ratio, along with a high 
content of complex carbohydrates and fibers. Ancel 
Keys, who conducted large multinational studies in 
the 1950s­1980s[22­24], first reported a lower mortality 
rate from CVD and cancer among people living in 
Greece ­ as well as in certain parts of Italy and the 
former Yugoslavia ­ in comparison to other populations. 
Afterwards, other studies have confirmed these findings, 
recognizing MD as a healthy and useful diet for reducing 
the risk of CVD and cancer[25­28] as well as of obesity 
and type 2 diabetes[29]. Yet, MD has been proposed 
as a longevity determinant in these populations[30]. 
Many studies suggest that the protective effects of MD 
may be due mostly to the anti-inflammatory and anti-
oxidant properties of its components. In particular, 
the capacity of MD to reduce the risk of development 
and progression of NAFLD has been attributed to 
the nutraceutical effect of bioactive compounds and 
phytochemicals with antioxidant and anti-inflammatory 
capacity such as fibers, monounsaturated and omega-3 
fatty acids and phytosterols[31,32]. NAFLD is associated 
with visceral obesity, insulin resistance, dyslipidemia, 
and chronic inflammation all of which are features 
of Mets. MD may improve NAFLD by modulating 
the presence of these conditions. In particular, the 
antioxidant and anti­inflammatory effects as well as 
the lipid­lowering effects and gut­microbiota­mediated 
production of metabolites are the principal mechanisms 
by which MD can influence metabolic health as well as 
NAFLD.
CLINICAL STUDIES ON MEDITERRANEAN 
DIET IN NAFLD PATIENTS
Cross sectional studies 
Recently, researchers have focused on the possible 
association between MD and NAFLD. Data from cross 
sectional studies suggest that MD components have 
a beneficial effect on NAFLD[33]. As such, the EASL­
EASD­EASO clinical Practice Guidelines have recently 
encouraged MD as a lifestyle choice for treating the 
disease[16]. The available studies are presented in Table 
1[34­40]. Kontogianni et al[34] were the first to explore the 
potential impact of MD on NAFLD and its severity in 73 
overweight/obese adult patients, of whom 34 had liver 
biopsies. They found that the MD score was inversely 
associated to serum alanine aminotransferase (ALT) 
and insulin concentrations as well as to histological 
characteristics of severe steatosis. A higher adherence 
to MD (as determined by MedDietScore) was not 
followed by a lower likelihood of having NAFLD, even 
after adjustment for abdominal fat level. However, it was 
associated with a less severe liver disease[34]. Indeed, 
patients with nonalcoholic steatohepatitis (NASH) were 
less likely to adhere to MD (P = 0.004) versus patients 
without NASH. Limitations of the study are the cross­
sectional design which enables to establish a casual 
relation; the small sample size; and patients’ selection 
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Table 1  Traditional Mediterranean diet components
Components Consumption Rich in
Fresh fruits Daily, 3 servings Vitamin C, polyphenols, 
carotenoids, fibers
Vegetables Daily, 6 servings Vitamin C, polyphenols, ω-3-
PUFA, carotenoids, fibers
Olive oil Daily1 MUFA, polyphenols
Unrefined cereals Daily, 8 servings Polyphenols, fibers
Nuts Weekly Polyphenols, ω-3-PUFA, 
fibers
Legumes Weekly, ≥ 3 servings Polyphenols, fibers
Fish Weekly, 5-6 servings ω-3-PUFA
Red wine Weekly, ≥ 7 glasses Polyphenols
1As the main added lipid.
Anania C et al . Mediterranean diet and NAFLD
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severity by ultrasound; and failure to include physical 
activity level[39]. Very recently, Della Corte et al[40] analyzed 
the adherence to MD (as assessed by the KIDMED score) 
in 243 overweight/obese youths with and without NAFLD. 
Of these, 100 underwent liver biopsy. Poor adherence 
to MD was related to severity of liver damage as well as 
to higher levels of C­reactive protein (CRP), insulin and 
HOMA­IR values, homeostatic model assessment of β 
cell function and blood pressure levels, thus suggesting 
increased inflammatory potential of unhealthy diets[40]. 
Lack of a normal weight control group as well as failure 
to adjust for confounding variables are major limitations 
of this study.
CLINICAL STUDIES ON MEDITERRANEAN 
DIET IN NAFLD PATIENTS
Longitudinal studies 
Longitudinal studies are available, to our knowledge, 
only in adult patients (Table 3)[33,41­46]. Fraser et al[41] in 
a quasi­randomized trial evaluated the effect of three 
different dietary interventions [the 2003 recommended 
American Diabetes Association diet; a low glycemic index 
(LGI) diet; and a modified MD] on ALT concentrations in 
259 individuals with obesity and type 2 diabetes. Food­
energy intake was similar across all three diets,but diet 
profiles differed in fat and carbohydrate components. 
The lowest ALT level at 6 and 12 mo of follow­up was 
achieved after MD intervention, independently of weight 
loss, HOMA­IR or triacylglycerol values[41]. In a very 
small, randomized, cross­over intervention trial involving 
12 non­diabetic patients with biopsy­diagnosed NAFLD, 
Rayan et al[42] compared MD to an isoenergetic standard 
low fat­high carbohydrate diet. After 6 wk of treatment, 
patients experienced after MD intervention a 38% re­
duction in liver steatosis (as assessed by 1H­MRS) and 
improvement of insulin sensitivity compared to patients 
on low­fat, high­carbohydrate diet, independently of 
weight loss or waist circumference changes[42]. In a 
randomized,controlled study involving adult subjects 
wth type 2 diabetes, Bozzetto et al[43] evaluated the 
effects of an isoenergetic MUFA diet versus a diet higher 
in carbohydrate and fiber. They found that the hepatic 
fat content (as measured by 1H­MRS before and after 
8 wk of intervention) significantly decreased with MUFA 
diet, independently of exercise. Subsequently, in a 
single arm trial including 90 overweight NAFLD patients, 
Trovato et al[44] evaluated the Bright Liver Score at 
baseline and 1, 3, and 6 mo after MD intervention. 
Over the 6­mo period, adherence to MD resulted in a 
significant reduction of liver fat content, independently 
of other lifestyle changes[44]. In a 6­mo randomized 
controlled study, Abenavoli et al[45] compared three 
groups of overweight patients with ultrasound­diagnosed 
NAFLD who received either MD alone (n = 10), or MD 
supplemented with the Reasil complex including silybin 
(an extract of Silybum marianum commonly known as 
criteria (elevated ALT, and ultrasound diagnosis of fatty 
liver and its severity). Similarly, in a study including 82 
adult subjects with biopsy­proven NAFLD, Aller et al[35] 
demonstrated that patients with greater adherence to 
MD (as determined by the 14­item MD assessment 
tool) were less likely to present histological features of 
severe steatosis and NASH, as well as to have severe 
insulin resistance. In a population­based study involving 
797 apparently healthy Chinese adults, Chan et al[36] 
evaluated the relationship between two diet­quality 
scores [Diet Quality Index­International (DQI­I) and MD 
score] in subjects with (n = 220) and without (n = 577) 
NAFLD [as established by proton­magnetic resonance 
spectroscopy (1H­MRS)]. DQI­I, but not the MD score, 
was significantly related to the NAFLD prevalence, 
and this association was stronger in overweight/obese 
versus normal weight subjects. Lack of an association 
between MD and NAFLD prevalence can be explained 
by the fact that the intake of certain foods such as milk 
and milk products, olive oil, wine and nuts was lower in 
this study cohort than in the traditional MD[36]. Although 
the study by Chan et al[36] included a relatively large 
sample size and the diagnosis of NAFLD was achieved 
by 1H­MRS, its major limitation is represented by lack 
of adjustment in the analysis of lifestyle factors such 
as physical activity. Recently, Trovato et al[37] in a study 
involving 1199 overweight/obese adult patients [with 
(n = 532) and without (n = 667) ultrasound­diagnosed 
hepatic steatosis] found that NAFLD patients were 
less likely to be adherent to MD. Notably, poor MD 
adherence strongly predicted the occurrence of NAFLD, 
independently of body mass index (BMI), homeostatic 
model assessment of insulin resistance (HOMA­IR), and 
physical activity score. Very recently, Baratta et al[38] 
showed that MD adherence was inversely related to 
NAFLD prevalence (as assessed by ultrasound) in a large 
cohort of overweight/obese adults with cardio­metabolic 
risk. Subjects with intermediate to high adherence to 
MD were less likely to have NAFLD and more likely to 
improve cardio­metabolic features[38]. Again, limitations 
of the last two studies include their cross­sectional study 
design; lack of a normal weight control group; and use 
of ultrasound for diagnosing NAFLD.
In children (Table 2), there are only two studies on the 
association between NAFLD and MD[39,40]. Cakir et al[39] 
first analyzed in obese youths the association between 
MD adherence [as assessed by the Mediterranean Diet 
Quality Index (KIDMED)] and NAFLD (as diagnosed 
by ultrasound and/or elevated ALT levels, as well as by 
exclusion of other causes of fatty liver disease). The 
authors evaluated overweight/obese children with (n = 
106) and without (n = 21) NAFLD, as well as children 
(n = 54) with normal BMI and without known chronic 
disease. Subjects with a low MD adherence were more 
likely to present with a higher BMI, though no correlation 
was found with other parameters including steatosis 
severity. Limitations of the study are the cross­sectional 
design; the small sample size; assessment of fatty liver 
Anania C et al . Mediterranean diet and NAFLD
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milk thistle), phosphatidylcholine and vitamin E (n = 
10), or no pharmacological and nutritional treatment 
(n = 30) . After 6 mo of follow­up, MD either alone 
or in association with the Realsil complex resulted in 
significant improvement in fat accumulation as well 
as in BMI, waist circumference, total cholesterol, 
Authors, year, 
country[ref.]
Patient population NAFLD Diagnosis Adherence to MD Comment 
Kontogianni, 
2014, Greece[34]
73 overweight/obese 
adult patients with 
NAFLD vs 58 age-, 
gender-, and BMI-
matched controls with 
normal liver ultrasound/
liver chemistry 
Patients who met all the 
following criteria: abnormal 
ALT and/or GGT; ultrasound 
evidence of hepatic steatosis 
and/or compatible liver 
histology; and no other cause 
of liver steatosis
Adherence to MD (as estimated 
by MedDietScore) did not differ 
significantly between patients and 
controls
Higher adherence to MD was not 
associated with lower likelihood of 
having NAFLD (even after adjustment 
with abdominal fat level). However, 
it was associated with lesser degree of 
insulin resistance and less severe liver 
disease among patients with NAFLD
Aller, 2015, 
Spain[35]
82 adult patients with 
NAFLD (of whom 56 
had NASH, and 26 non-
NASH; 35 had steatosis 
grade 1, and 47 steatosis 
grades 2 and 3)
Liver biopsy in all 82 patients Higher adherence to MD (as estimated 
by the 14-item MD assessment tool) 
was higher in patients with low grade 
of steatosis than in those with high 
grade, in patients without NASH than 
in those with NASH, and in patients 
without liver fibrosis than in those with 
liver fibrosis
In the logistic regression analysis,one 
unit of the 14-item MD assessment 
tool was associated with a lower 
likelihood of having NASH (OR = 
0.43) and steatosis (OR = 0.42)
Chan, 2015, 
Hong Kong[36]
797 apparently healthy 
Chinese adults (332 male, 
465 female) of whom 220 
(27.6%) had diagnosis of 
fatty liver
1H MRS was performed to 
measure IHTG.
Fatty liver was defined as 
IHTG ≥ 5%
Subjects with fatty liver showed lower 
gender-adjusted MD score than those 
without fatty liver
Multivariate adjusted regression 
analyses showed an inverse 
association between MD score and 
prevalence of fatty liver, which 
approached the level of significance
Trovato, 2016, 
Italy[37]
1199 overweight/ obese 
adult patients with (n 
= 532) and without (n = 
667) hepatic steatosis
Hepatic steatosis and its 
severity were assessed by 
ultrasound 
Greater prevalence of overweight/ 
obesity (as assessed by BMI) and 
insulin resistance (as assessed by 
HOMA-IR), sedentary life habits, 
increased TG and HDL-C, greater use 
of Western diet food, as well as poor 
adherence to MD (as assessed by 1-wk 
recall questionnaire) were found in 
patients with hepatic steatosis vs those 
without it
Multiple regression analysis, 
weighted by years of age, displayed 
BMI, HOMA-IR and adherence to MD 
as the most powerful predictors of 
hepatic steatosis severity
Baratta, 2017, 
Italy[38]
584 overweight/obese 
adult patients with ≥ 1 
CVD risk factor
Ultrasound evaluation 57 (9.8%) patients had low MD 
adherence (as estimated by Med-
Diet questionnaire), while 436 (74.6%) 
and 91(15.6%) had, respectively, 
intermediate and high MD adherence.
NAFLD prevalence significantly 
decreased from subjects with low to 
high adherence to MD (from 96.5% to 
71.4%, P < 0.001)
In a multiple logistic regression 
analysis, MD adherence (intermediate 
vs low OR = 0.115; P = 0.041; high 
vs low OR: 0.093; P = 0.030) were 
independently associated with 
NAFLD
Cakir, 2016, 
Turkey[39]
Overweight/obese 
children with (n = 106, 
Group 1) and without (n 
= 21, Group 2) hepatic 
steatosis; and children 
with normal BMI and 
without known chronic 
disease (n = 54, Group 3)
Assessment of hepatic 
steatosis and its severity by 
ultrasound
Prevalence of a low level of MD 
adherence (as established by KIDMED 
index score) was significantly higher 
in Group 1 children compared to those 
belonging to Groups 2 or 3 
The level of adherence to MD was 
negatively correlated with BMI, but 
no significant correlation was found 
with ALT, total body fat, TG, and 
HOMA-IR.
No significant difference in the level 
of MD adherence was found between 
patients with hepatic steatosis grade1 
and those with grades 2 and 3
Della Corte, 
2017, Italy[40]
4 subgroups of 
overweight/obese 
children: with and 
without fatty liver; with 
and without NASH. 
Among the 243 study children, 
ultrasound identified and 
excluded fatty liver in 66 and 
77, respectively. 
The remaining 100 underwent 
liver biopsy identifying and 
excluding NASH in 53 and 47, 
respectively
Prevalence of a low level of adherence 
to MD (as estimated by KIDMED score) 
was significantly higher in patients 
with NASH compared to those without 
NASH as well as to those with and 
without fatty liver (100% vs 28.8% vs 
37.9% vs 9.1%; P = 0.01)
Poor adherence to MD was associated 
to severe liver damage, with a 
negative correlation with NAFLD 
activity score and fibrotic stage 
ALT: Alanine aminotransferase; BMI: Body mass index; CVD: Cardiovascular disease; GGT: Gamma-glutamyl transferase; 1H MRS: Proton magnetic 
resonance spectroscopy; HOMA-IR: Homeostasis model assessment of insulin resistance; IHTG: Intrahepatic triglyceride content; MD: Mediterranean diet; 
NAFLD: Non-Alcoholic Fatty Liver; NASH: Non-Alcoholic Steatohepatitis; OR: Odds ratio; TG: Triglycerides. 
Table 2  Cross sectional studies on the association between Mediterranean diet and non-alcoholic fatty liver disease
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Table 3  Longitudinal studies on the effects of Mediterranean diet on non-alcoholic fatty liver disease in adult patients
Authors, year, 
country[ref.]
Study design Patient population Intervention (duration, 
type, number of patients)
Liver outcome Other outcomes 
Fraser, 2008, 
Israel[41]
An open label, 
parallel design, 
quasi-randomized 
(allocation by 
alternation) 
controlled trial
Overweight /obese 
patients with T2DM
3 groups at 6/12 mo: 
1. ADA diet, n = 64/54; 
2. Low GI diet, n = 73/64; 
3. Modified MD, n = 64/61. 
Energy contents similar in 
all three diets
ALT levels significantly 
decreased at 6 and 12 mo in 
modified MD vs low GI or ADA 
diets, independently of waist 
to hip ratio, BMI, HOMA and 
triacylglycerol values
Bozzetto, 
2012, Italy[43]
Randomized, 
controlled, 
parallel-group 
design
36 overweight /obese 
patients with T2DM
8 wk, 4 groups: 
1. High-CHO/ high-fiber/ 
low GI diet, n = 9; 
2. MUFA diet, n = 8; 
3. High-CHO/ high-fiber/ 
low GI diet + exercise, n = 
10; 
4. MUFA diet + exercise, n 
= 9.
Liver fat (as measured by 1H 
MRS) decreased more in groups 
2 (-25%) and 4 (-29%) than in 
groups 1 (-4%) or 3 (-6%). 
Two-way repeated-measures 
ANOVA showed a significant 
effect on liver fat content for 
MUFA diet, independently of 
exercise. 
There were no significant ALT 
and AST changes in all groups.
At the end of intervention, there 
were no significant changes in 
body weight,WC, as well as in 
glucose, total cholesterol, LDL-C, 
HDL-C, TG, and HOMA-
IR values from baseline in all 
groups
Ryan, 2013, 
Australia[42]
A randomized, 
controlled, cross-
over study
12 non-diabetic 
patients with a biopsy-
proven NAFLD at 
baseline
A cross-over 6-wk dietary 
intervention study 
comparing traditional MD 
vs low fat/high-CHO 
MD group demonstrated a 
significant decrease in liver 
fat (as measured by 1H MRS) 
compared to the low fat/ high-
CHO group (39% vs 7%). 
ALT and GGT did not 
significantly decrease with either 
diet
At the end of intervention, no 
significant changes in body 
weight, WC, as well as in TG, 
and HDL-C in both groups. 
Peripheral insulin sensitivity 
improved only in the MD group. 
Systolic BP declined significantly 
in both groups, though to a 
lesser degree in the low fat/ 
high-CHO group
Trovato, 2015, 
Italy[44]
Single arm Non-diabetic 
overweight/obese 
patients with 
ultrasound evaluation 
of liver fat changes 
from baseline
90 patients following 
intervention with MD 
alone for 1, 3, and 6 mo
Liver fat significantly decreased 
only after 6 mo of intervention. 
By a multiple linear regression 
model, changes in adherence to 
the MD and BMI were found 
to independently explain the 
variance of decrease of liver fat 
(R2 = 0.519; P < 0.0001).
No significant ALT changes 
were observed throughout the 
follow-up
Significant decrease of BMI 
followed by parallel increases 
of the MD adherence as well 
as of physical activity were 
observed from the first month of 
intervention. 
Significant decrease of HOMA-
IR was observed only after 3 and 
6 mo 
Abenavoli, 
2015, Italy[45]
Controlled 
randomized 
study
Overweight/obese 
patients with 
ultrasound evaluation 
of liver fat changes 
from baseline 
6 mo, 3 groups: 
1. Hypocaloric MD, n = 10; 
2. Hypocaloric MD plus 
Realsil complex, n = 10; 
3. No treatment, n = 10.
Compared to the group that 
did not undergo any treatment, 
MD either alone or associated 
with the Realsil complex led to 
significant improvement in liver 
steatosis
Compared to the group that did 
not undergo any treatment, those 
following the MD either alone 
or associated with the Realsil 
complex had improvement in 
BMI, WC, hip circumference, as 
well as in total cholesterol, and 
TG. 
Improvement in insulin 
sensitivity occurred only in 
patients receiving MD plus the 
Reasil complex
Misciagna, 
2016, Italy[46]
Randomized, 
controlled, 
parallel-group 
design
A population almost 
composed of non-
diabetic overweight/ 
obese patients (18 to 
79 years old, without 
overt CVD) with 
ultrasound evaluation 
of liver fat at baseline 
and follow-up
3 and 6 mo, 2 groups: 
1. MD with low GI, n = 44; 
2. Control diet(based on 
INRAN guidelines), n = 46
MD with low GI was associated 
until 55 yr of age, in both men 
and women, with a more intense 
reduction in liver fat than a 
control diet, at both the 3rd and 
6th month 
Six months after intervention, 
in both groups, the number of 
obese patients decreased while 
the number of overweight 
subjects increased.
Lower TG and glucosemia were 
found at 6 mo in both groups
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triglyceride and insulin resistance values[45]. In a 
randomized controlled study, Misciagna et al[46] com­
pared two groups of non­diabetic overweight­obese 
patients with moderate/severe ultrasound­diagnosed 
NAFLD who followed, respectively, a control diet (based 
on the Italian National Research Institute guidelines) 
and a low glycemic Index Mediterranean Diet (LGIMD). 
Compared to the control diet, LGIMD resulted in a major 
reduction of liver fat at both 3th and 6th month[46]. Finally, 
very recently, in a single arm, observational study, Gelli 
et al[33] treated with MD 46 normal weight (n = 11) or 
overweight/obese (n = 35) patients with NAFLD. They 
determined liver enzymes, metabolic parameters, CVD 
risk indexes, and ultrasound­based NAFLD severity. At 
the end of treatment, the proportion of patients with 
liver steatosis grade ≥ 2 was reduced from 93% to 
48%. Also, metabolic parameters and liver enzymes 
decreased significantly[33]. 
Several points need be considered when interpreting 
the results of the aforementioned studies. First, they 
were based on high­risk populations, therefore not 
representative of the general population. Second, most 
of them were based on a small sample size. Notably, 
none of the studies provided information on how sample 
size was calculated and how participants were randomly 
assigned to the intervention groups. As matter of fact, 
there may be synergistic and antagonistic interactions 
among food components of MD that may be difficult to 
detect unless very large samples are used. Third, MD 
includes a variety of eating patterns and, therefore, a 
wide range in assessment score items. As such, using a 
score for assessment of adherence to a dietary pattern 
is limited by subjectivity, leading therefore to a great 
variability in interpretation of study results. Fourth, 
the majority of studies utilized ultrasonography that is 
known to be highly operator­dependent, and to have 
limited repeatability and reproducibility. In addition, 
ultrasonography has shown low accuracy in assessing 
severity of liver disease including presence and extent of 
fibrosis[47]. Fifth, most studies failed to take into account 
total energy intake. Finally, most studies failed to adjust 
for potential confounders including physical activity, and 
socioeconomic and cultural levels, which might have 
influenced lifestyle habits of the population studied.
BIOLOGICAL MACHANISMS OF 
MEDITERRANEAN DIET
Anti-inflammatory and antioxidant effects of MD 
components
MD is based on compounds, such as polyphenols, 
vitamins and other biomolecules that have anti­
inflammatory and antioxidant effects. This seems to be 
relevant, since inflammation and oxidative stress play a 
central role in the pathogenesis of NAFLD/NASH. 
Polyphenols are present in whole­grain cereals, 
vegetables and fresh fruits, olive oil, nuts and red 
wine. They are a heterogenic group of bioactive com­
pounds, including several hydro­soluble antioxidants, 
characterized by a phenolic structure[48]. Based on 
their chemical structure, there are two categories of 
polyphenols: flavonoid polyphenols, and the non­
flavonoid polyphenols[49]. 
Flavonoids are polyphenolic compounds that are 
ubiquitously found[50] and provide much of the flavor 
and color to fruits and vegetables. They have hepato­
protective effects in view of their antioxidant and anti­
inflammatory potential[49,51­53]. Among non­flavonoids, 
resveratrol, a stilbene polyphenol content in red wine, 
has been shown to exert hepato­protective activity 
by affecting the three interacting components of 
homeostasis such as the vessel, the blood platelets and 
the clotting and the fibrinolytic system of plasma[54,55]. 
Vitamins, which are significant components of MD, 
can also be considered dietary antioxidants. They 
reduce cellular stress and, in this way, they have a 
pivotal role in preventing NAFLD progression. Vitamin 
E has been shown to improve histological features of 
NASH[56­59]. Vitamin D has immunomodulatory, anti­
inflammatory and anti-fibrotic properties while vitamin D 
supplementation has been demonstrated to ameliorate 
NAFLD histopathology[60,61]. When incubated with isolated 
rat liver, vitamin C has been shown to decrease levels of 
mitochondrial reactive oxygen species generation, and 
to increase the levels of antioxidant enzymes and the 
activity of the electron transport chain[62]. 
Carotenoids are also part of MD; they comprise a class 
of natural fat­soluble pigments acting as antioxidants, 
ADA: American Diabetes association; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; BP: Blood pressure; 
CHO: Carbohydrates; GGT: Gamma-glutamyl transferase; GI: Glycemic index; 1H MRS: Proton magnetic resonance spectroscopy; HDL-C: High density 
lipoprotein-cholesterol; HOMA-IR: Homeostasis model assessment of insulin resistance; INRAN: Italian National Research Institute for Foods and 
Nutrition; LDL-C: Low density lipoprotein-cholesterol; MD: Mediterranean diet; MetS: Metabolic syndrome; MUFA: Monounsaturated fatty acid; T2DM: 
Type 2 diabetes mellitus; TG: Triglycerides; WC: Waist circumference.
Gelli, 2017, 
Italy[33]
Single arm 46 (11 normal weight; 
35 overweight/obese) 
subjects (42 with ≥ 
1 MetS component; 
4 with T2DM) with 
ultrasound evaluation 
of liver fat at baseline 
and follow-up
All patients followed 
intervention with MD 
alone for 6 mo
At end-intervention, the 
percentage of patients with 
hepatic steatosis grade ≥ 2 
was reduced from 93% to 48%; 
mean AST, ALT, GGT decreased 
significantly
At end of intervention, of the 35 
overweight/obese patients, 12 
showed ≥ 7% weight reduction 
while 7 achieved normal weight; 
mean serum total cholesterol, 
HDL-C, AST, TG, glucose 
concentrations, and HOMA-IR 
values significantly improved
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which are found in several fruits and vegetables[63]. Among 
them, lycopene has been investigated as a potential 
protective agent in NAFLD in view of its potent antioxidant 
effects[64]. Studies in lycopene­fed rats have shown that 
lycopene has a preventive effect on experimental NASH by 
reducing steatosis and inflammation as well as oxidative 
stress[65].
Lipid-lowering effect of MD components
The beneficial effects of MD on the hepatic lipid 
metabolism and, consequently, on NAFLD prevention, 
is influenced primarily by its fatty acid composition 
which is characterized by high MUFA content with a 
balanced PUFA omega­6 to omega­3 ratio due to the 
abundance of vegetables, legumes, nuts, olive oil and 
fish (instead of red meats)[66]. It has been proved that 
MUFA intake may prevent the development of NAFLD 
by improving plasma lipid levels, reducing body fat 
accumulation and decreasing postprandial adiponectin 
expression[67,68]. PUFA regulate three major transcriptional 
factors controlling multiple pathways involved in hepatic 
carbohydrate and lipid metabolism. PUFA activation of 
hepatic peroxisome proliferator­activated alpha (PPARα) 
enhances fatty acid oxidation, while PUFA suppression of 
sterol regulatory element binding protein­1 (SREBP­1) 
and of carbohydrate regulatory element binding protein 
(ChREBP)/Max­like factor X (MLX) results in the inhibition 
of glycolysis and of de-novo lipogenesis. As such, PUFA 
promote a shift in metabolism toward fatty acid oxidation 
and away from fatty acid synthesis and storage, and may 
positively affect NAFLD[69,70]. In addition to improvement 
in steatosis, PUFA may induce an independent, anti­
inflammatory effect via suppression of tumor necrosis 
factor and interleukin-6, responsible for the inflammation 
occurring in NASH[71]. Opposite health effects have been 
found regarding the role of n­6 PUFA on NAFLD. N­6 
PUFA, such as linoleic acid may have a pro-inflammatory 
role due to their direct relation with the production of 
arachidonic acid (AA). AA is metabolized to give rise to 
the eicosanoid family of inflammatory mediators (e.g. 
prostaglandins, leukotrienes and related metabolites), 
and through these to regulate the production of 
inflammatory cytokines[72]. Excessive amounts of 
omega­6 PUFA and a very high omega­6 to omega­3 
ratio have been involved in the pathogenesis of many 
diseases, including CVD, cancer, and inflammatory and 
autoimmune diseases[73]. A proportionally high intake of 
n­6 PUFA is considered pro­inflammatory and possibly 
associated with an increased risk of MetS. Therefore, not 
only PUFA intake but also the n­6 PUFA to n­3 PUFA ratio 
is relevant. 
Several studies have shown that a reduced intake of 
saturated fat is associated with a reduction of plasma 
concentrations of total cholesterol, very low density 
lipoprotein (LDL)­cholesterol and triglycerides[74]. 
MD can also contribute to lowering plasma cho­
lesterol by high consumption of water­soluble fibers 
which are found in large concentration in some MD 
components, mainly beans, vegetables and fruits and 
whole­grain cereals. Water­soluble fibers have been 
shown to increase the rate of bile excretion therefore 
reducing serum total and LDL cholesterol[75].
GUT MICROBIOTA AND MD 
COMPONENTS
The liver is closely connected to the gut as it receives 
about 70% of its blood supply directly from the 
intestine via the portal vein. Therefore, it is one of the 
organs mostly exposed to gut­derived toxic products, 
such as bacteria and bacterial derivates. This cross­
talking between the intestine and the liver is known 
as the “gut­liver axis” and has been linked to liver 
pathologies, including NAFLD. The relationship between 
NAFLD and altered microbiota is mainly supported 
by studies on animal models[76,77].There are limited 
data in humans[78,79]. Gut microbiota plays a crucial 
role in the complex pathogenesis of NAFLD through 
a variety of mechanisms such as predisposition to 
obesity, induction of insulin resistance as well as of liver 
inflammation, and alteration of choline metabolism[80]. 
Other mechanisms include increased microbiome­
modulated metabolites such as bile acids, short chain 
fatty acids, lipopolysaccharides as well as dysbiosis­
induced intestinal barrier dysfunction[81]. Many different 
factors may influence microbiota composition, including 
age, comorbid conditions, host genotype and exposure 
to antibiotics, and dietary habits[82]. Diet largely 
influences gut microbiota and its products[83]. Specific 
dietary factors, such as macronutrient composition (e.g. 
increased protein intake), food type (e.g. glycemic index 
or load) or the presence of specific bioactive compounds 
(omega-3 fatty acids, fibers or polyphenols) have been 
shown to influence the diversity and functionality of 
the gut microbiota[84]. Also protein, insoluble fibers and 
fat content have important effects on gut microbiota 
structure, function, and its secretion of metabolites that 
modulate immune function and multiple metabolic and 
inflammatory pathways[85­87]. Therefore, MD may have 
a significant impact on the composition and diversity of 
the microbiota. As MD is characterized by a high dietary 
fiber intake, it promotes beneficial modification of the 
gut microbiota with decreased Firmicutes and increased 
Bacteroides, which have been shown to ameliorate 
obesity, inflammation and related metabolic alterations. 
Polyphenols contained in MD induce an increase in 
Bifidobacteria, associated with various metabolic 
benefits such as plasma cholesterol reduction and a 
decrease of C­reactive protein (CRP)[88]. Gut microbial 
production of trimethylamine N­oxide from dietary 
choline and l­carnitine enhances the risk of developing 
CVD in both animals and humans, independently of 
CVD risk factors[89]. MD benefits on the gut microbiota 
could also be the consequence of a low content of 
choline and l­carnitine in MD diet. 
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CONCLUSION
MD, low in saturated fats and animal protein, high in 
antioxidants, fiber and MUFA, and with an adequate 
omega­3 to omega­6 fatty balance, represents an 
healthy dietary pattern, which has been shown to 
decrease CVD, MetS, and type 2 diabetes. Although MD 
seems particularly attractive for its potential to improve 
liver status, literature concerning the efficacy of this 
dietary pattern in patients with NAFLD is still limited to 
few cross­sectional as well as to few longitudinal studies 
with certain limitations. In particular, longitudinal 
studies have included small sample size, short­term 
follow­up, different designs, different time points of 
data collection, and above all poor methodology for 
reporting the trial or diagnosing the liver outcome and 
its associated comorbidities, anyone of which or any 
combination of which may limit the generalizability of 
study results. There is room for adequate randomized 
dietary intervention trials comparing MD with a control 
diet in a large sample of the general population, 
along with a validation of the MD indexes in the 
heterogeneous patient population with NAFLD.
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